AbstractPurpose of review
Availability of direct acting antivirals (DAAs) that demonstrate remarkable clinical efficacy and safety has revolutionized the ability to treat chronic infection with hepatitis C virus (HCV). An equal measure of clinical success has now been achieved in persons coinfected with HCV and the HIV, a historically harder to cure cohort with interferon-based therapy. Global goals include identifying all HIV–HCV-infected persons, gaining access to DAA therapy, preventing de novo and reinfection, and managing the sequelae of chronic infection. This review will discuss advances in the field of HIV–HCV coinfection reported during the last 18 months, and will suggest areas for future investigation.Recent findings
An expanding body of literature has enhanced our understanding of the clinical and epidemiologic issues surrounding HIV–HCV coinfection. DAA therapy for HCV is highly efficacious in HIV–HCV-coinfected persons if drug–drug interactions are appropriately considered.Summary
Eradicating HCV infection in persons with HIV coinfection can be achieved safely and effectively with available DAAs. Economic and social approaches to enable access and delivery of curative HCV therapy to HIV-infected persons require continued research and resource allocation.